The efficAcy and safety of Trimetazidine in Patients with angina pectoris having been treated by percutaneous Coronary Intervention. ATPCI study An international, multicentre, randomised, double-blind, placebo-controlled study in patients treated for 2 to 4 years. - ATPCI study

Servier0 个研究点目标入组 200 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•Women or men >= 21 years old and < 85 years old of any ethnic origin.
•Patients presenting a single or multivessel coronary artery disease and having undergone PCI treating at least one stenosis to either a native coronary artery or a coronary graft where the PCI was:
•- indicated because of angina pectoris occurring either in the context of stable angina (elective PCI) or in the context of an acute presentation such as unstable angina/NSTEMI, but excluding STEMI;
•- achieved by stent implantation or by other acceptable interventional means;
•- successful as planned by the operator and with no further revascularization (either percutaneous or surgical) planned;
•- uncomplicated such that the patient's discharge was not, or will not be, delayed because of a cardiac or cerebrovascular problem

•- Severe uncontrolled rythm disturbances including paroxysmal VT and SVT;- Known severe aortic or mitral valve disease;
•- Clinical signs and/or symptoms of heart failure corresponding to NYHA class IV;
•- Hypertrophic obstructive cardiomyopathy or other forms of left ventricular outflow tract obstruction;
•- Active myocarditis, pericarditis or endocarditis;
•- Hystory of agranulocytosis, severe thrombocytopenia or severe coagulation disorder;
•- History of pulmonary embolism within preceding 6 months;
•- Known severe uncontrolled arterial hypertension;
•- Known chronic severe or moderate renal failure, with sCrCl < 60 mL/min or eGFR<60 mL/min/1.73m²;
•- Current or previous movement disorders such as Parkinsonian symptoms, restless leg syndrome, tremor, gait instability of central origin

发起方